Immuron leaps 80pc after announcing Phase 2 results for Travelan. Picture Getty
Health & Biotech
Immuron (ASX:IMC) jumped by over 80% this morning after announcing interim topline results confirming the efficacy of Travelan in preventing diarrhoea following enterotoxigenic Escherichia coli (ETEC).
The Phase 2 study on 60 patients show that a single daily dose of Travelan is 36.4% effective in the prevention of moderate to severe diarrhoea induced by ETEC, when compared to the placebo group in the study.
Around 66.7% protective efficacy against ETEC-induced severe diarrhoea was also observed in the patients taking Travelan, compared to the placebo group (secondary endpoint).
Results also demonstrated a 83.3% statistically significant reduction in the number of subjects in the Travelan group requiring early antibiotic treatment post-ETEC, compared to the placebo group.
This was particularly significant as all (100%) taking placebo required IV fluids post-ETEC challenge.
Finally, there was 55.6% reduction in the number of patients experiencing adverse events associated with the ETEC challenge observed in the Travelan group, compared to the placebo group.
Immuron says these results will support the progress of Travelan into a Phase 3 trial.
Doctor Care Anywhere (ASX:DOC) surged as much as +11% this morning after announcing the appointment of Ben Kent as its new CEO, following a successful year as interim CEO.
He also joins the board of directors as an executive director.
Seema Sangar has also been appointed as CFO, having previously held finance director roles at Equiniti Group plc and Avast Plc.
DOC is one of the UK’s largest private providers of telehealth services.
The company lost its former CEO, Bayju Thakar, in late 2022 before Kent took over as interim CEO in March 2023.
Health & Biotech
Health & Biotech
Health & Biotech
Get the latest Stockhead news delivered free to your inbox.
